📊 ALDX Key Takeaways
Is Aldeyra Therapeutics, Inc. (ALDX) a Good Investment?
Aldeyra Therapeutics is a pre-revenue biopharmaceutical company burning substantial cash with negative operating margins of -35.3M and no commercial revenue generation. While the company maintains adequate liquidity with 70.0M in cash, the current cash burn rate of -33.3M annually suggests only 2+ years of runway, and the complete absence of revenue indicates the company has not yet achieved clinical or commercial success. The negative ROE of -76.5% and deteriorating financial position present significant fundamental concerns.
Aldeyra Therapeutics shows the typical profile of a clinical-stage biotech: no meaningful revenue, persistent operating losses, and negative cash flow, but a balance sheet still supported by substantial cash relative to liabilities. Fundamentals are weak on profitability and returns, yet near-term financial health is not distressed, so the company looks more like a cash-funded development story than a fundamentally broken balance sheet.
Why Buy Aldeyra Therapeutics, Inc. Stock? ALDX Key Strengths
- Strong liquidity position with 70.0M in cash equivalents
- Conservative leverage with debt-to-equity ratio of 0.35x
- Current ratio of 2.58x indicates ability to meet short-term obligations
- Cash and equivalents of $70.04M cover most of the asset base and provide near-term operating flexibility
- Current and quick ratios of 2.58x indicate acceptable short-term liquidity
- Debt/equity of 0.35x is moderate and equity remains positive at $44.25M
ALDX Stock Risks: Aldeyra Therapeutics, Inc. Investment Risks
- No revenue generation - company is entirely pre-commercial
- Substantial ongoing operating losses of -35.3M with negative operating cash flow of -33.3M
- Limited cash runway of approximately 2+ years at current burn rate with no clear path to profitability
- Negative returns on equity (-76.5%) and assets (-47.0%) indicate shareholder value destruction
- Lack of insider purchases (zero Form 4 filings in 90 days) suggests limited confidence from management
- No revenue base means losses are not being offset by commercial execution or recurring cash generation
- Operating cash flow and free cash flow of -$33.35M imply continued cash burn and future financing risk
- ROE of -76.5% and ROA of -47.0% reflect very weak capital efficiency and poor profitability
Key Metrics to Watch
- Revenue generation timeline and magnitude from clinical development
- Cash burn rate trends and runway extension from partnerships or funding
- Operating expense reduction or clinical trial progression updates
- Debt maturity schedule and refinancing needs
- Insider buying activity as indicator of management confidence
- Cash runway relative to annual operating cash burn
- Revenue emergence or improvement in quarterly operating loss as pipeline programs advance
Aldeyra Therapeutics, Inc. (ALDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.58x current ratio provides a solid financial cushion.
ALDX Profit Margin, ROE & Profitability Analysis
ALDX vs Healthcare Sector: How Aldeyra Therapeutics, Inc. Compares
How Aldeyra Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aldeyra Therapeutics, Inc. Stock Overvalued? ALDX Valuation Analysis 2026
Based on fundamental analysis, Aldeyra Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aldeyra Therapeutics, Inc. Balance Sheet: ALDX Debt, Cash & Liquidity
ALDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aldeyra Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.94 indicates the company is currently unprofitable.
ALDX Revenue Growth, EPS Growth & YoY Performance
Aldeyra Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aldeyra Therapeutics, Inc. (CIK: 0001341235)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALDX
What is the AI rating for ALDX?
Aldeyra Therapeutics, Inc. (ALDX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALDX's key strengths?
Claude: Strong liquidity position with 70.0M in cash equivalents. Conservative leverage with debt-to-equity ratio of 0.35x. ChatGPT: Cash and equivalents of $70.04M cover most of the asset base and provide near-term operating flexibility. Current and quick ratios of 2.58x indicate acceptable short-term liquidity.
What are the risks of investing in ALDX?
Claude: No revenue generation - company is entirely pre-commercial. Substantial ongoing operating losses of -35.3M with negative operating cash flow of -33.3M. ChatGPT: No revenue base means losses are not being offset by commercial execution or recurring cash generation. Operating cash flow and free cash flow of -$33.35M imply continued cash burn and future financing risk.
What is ALDX's revenue and growth?
Aldeyra Therapeutics, Inc. reported revenue of N/A.
Does ALDX pay dividends?
Aldeyra Therapeutics, Inc. does not currently pay dividends.
Where can I find ALDX SEC filings?
Official SEC filings for Aldeyra Therapeutics, Inc. (CIK: 0001341235) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALDX's EPS?
Aldeyra Therapeutics, Inc. has a diluted EPS of $-0.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aldeyra Therapeutics, Inc. has a SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALDX stock overvalued or undervalued?
Valuation metrics for ALDX: ROE of -76.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALDX stock in 2026?
Our dual AI analysis gives Aldeyra Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALDX's free cash flow?
Aldeyra Therapeutics, Inc.'s operating cash flow is $-33.3M, with capital expenditures of $0.0.
How does ALDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -76.5% (avg: 15%), current ratio 2.58 (avg: 2).